Faeth Therapeutics, Inc (FTH) Stock AnalysisFTHStock AnalysisFaeth Therapeutics, Inc

Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib. It operates in the Healthcare sector.

Faeth Therapeutics appears to be a good buy right now, with a current price of $33.84 and a strong 5-day change of +5.75%. The RSI is at 63.079, suggesting bullish momentum. Additionally, analysts project a price target of $56, which represents a potential upside of approximately 65% from the current price. However, the main risk is the significant net loss reported for Q1 2026, which was -$170.2 million, indicating ongoing financial challenges that investors should monitor closely.